Table 2 Baseline characteristics of patients with diabetes and dilated cardiomyopathy with or without retinopathy
Variable | DR group | No DR group | P value |
|---|---|---|---|
No. of patients | 29 | 17 | Â |
Age (years) | 60.4 ± 9.3 | 61.8 ± 14.1 | 0.487 |
Male, N (%) | 17 (59%) | 12 (71%) | 0.417 |
Body mass index (kg/m2) | 23.5 ± 3.2 | 25.0 ± 3.0 | 0.136 |
Hypertension, N (%) | 19 (66%) | 9 (53%) | 0.399 |
Laboratory profiles | |||
 HbA1c (%) | 7.9 ± 1.8 | 7.4 ± 2.1 | 0.230 |
 Creatinine (mg/dL) | 3.1 ± 3.3 | 1.1 ± 0.5 | 0.007* |
 eGFR (mL/min/1.73 m2) | 43.1 ± 29.8 | 71.9 ± 25.1 | 0.003* |
 Total cholesterol (mg/dL) | 157.3 ± 36.2 | 190.8 ± 36.6 | 0.009* |
 Triglycerides (mg/dL) | 112.9 ± 55.1 | 163.6 ± 105.1 | 0.284 |
 HDL cholesterol (mg/dL) | 41.7 ± 12.2 | 50.9 ± 16.5 | 0.049* |
 LDL cholesterol (mg/dL) | 88.7 ± 37.6 | 100.6 ± 36.8 | 0.468 |
Medication | |||
 Anticoagulants | 18 (62%) | 14 (82%) | 0.149 |
 β-Blockers | 18 (62%) | 8 (47%) | 0.322 |
 ACEI/ARB | 25 (86%) | 15 (88%) | 0.844 |
 CCB | 1 (3%) | 0 (0%) | 0.439 |
 Diuretics | 19 (66%) | 9 (53%) | 0.399 |
 Statins | 11 (38%) | 4 (24%) | 0.315 |
 DPP4 inhibitors | 5 (17%) | 1 (6%) | 0.270 |
 Metformin | 7 (24%) | 3 (18%) | 0.606 |
 Sulfonylurea | 10 (34%) | 6 (35%) | 0.956 |